Detail akcie Valneva Sp ADS online

Business Summary: Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Valneva SE (ADR) revenues increased 3% to EUR174.7M. Net loss increased from EUR12.2M to EUR115.2M. Revenues reflect Technologies and Services segment increase from EUR1.1M to EUR10.1M, Licences segment increase from EUR712K to EUR3.4M, France segment increase from EUR7.2M to EUR14.7M, United States segment increase of 10% to EUR53.6M.